Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus

Nephrology Dialysis Transplantation

Volumn 20, Issue 11, 2005, Pages 2517-2523

  Bumbea, Viorica ^a   Kamar, Nassim ^a   Ribes, David ^a   Esposito, Laure ^a   Modesto, Anne ^a   Guitard, Joelle ^a   Nasou, Ghassan ^a   Durand, Dominique ^a   Rostaing, Lionel ^a  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Anaemia; Calcineurin inhibitor; Chronic allograft nephropathy; Creatinine; Renal function; Sirolimus

Indexed keywords

ADEFOVIR DIPIVOXIL; ALKALINE PHOSPHATASE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; CALCIUM; CHOLESTEROL; CREATININE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACTATE DEHYDROGENASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARATHYROID HORMONE; PHOSPHORUS; RAPAMYCIN; RECOMBINANT ERYTHROPOIETIN; STEROID; TACROLIMUS; URIC ACID;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTICLE; CALCIUM BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FACE EDEMA; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HEMOGLOBIN DETERMINATION; HEPATITIS B; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INTRACRANIAL HYPERTENSION; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RECIPIENT; RENAL GRAFT DYSFUNCTION; SKIN CANCER; THROMBOCYTOPENIA; URIC ACID BLOOD LEVEL;

BIOPSY; CALCINEURIN; CHRONIC DISEASE; CREATININE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SIROLIMUS; TACROLIMUS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 27644439969     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfh957     Document Type: Article

References (20)

1. Ojo AO, Held PJ, Port FK et al. Chronic renal failure after transplantation of a nomenal organ. N Engl J Med 2003; 349: 931-940
2. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723
3. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580-590
4. Nankivell BJ, Borrows RJ, Fung CL et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333
5. Bakker RC, Hollander AA, Mallat MJ et al. Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy. Kidney Int 2003; 64: 1027-1034
6. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action. Immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 31: 335-340
7. Mota A, Arias M, Taskinen EI et al. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004; 4: 953-961
8. Flechner SM, Goldfarb D, Modlin C et al. Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070-1076
9. Dominguez J, Mahalati K, Kiberd B, McAlister VC, MacDonald AS. Conversion to rapamycin immunosuppression in renal transplant recipients: Report of an initial experience. Transplantation 2000; 70: 1244-1247
10. Citterlo F, Scata MC, Violi P et al. Rapid conversion to sirolimus for chronic progressive deterioration of the renal function in kidney allograft recipients. Transplant Proc 2003; 35: 1292-1294
11. Diekmann F, Budde K, Oppenheimer F et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004; 4: 1869-1875
12. Amm J, Ramamurphy G, Degala A et al. Rapamycin substitution for calcineurin inhibitors in renal transplant recipients with chronic allograft nephropathy: A report on 57 cases. Am J Transplant 2003; 3 [Suppl 5]: 211
13. Morelon E, Kreis H. Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience. Transplant Proc 2003; 35: 52S-57S
14. English J, Evan A, Houghton DC, Bennett WM. Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation 1987; 44: 135-141
15. 2+ from intracellular stores. Hypertension 1997; 29: 222-227
16. Morales JM, Andres A, Dominguez-Gil B et al. Tubular function in patients with hypokalemia induced by sirolimus after renal transplantation. Transplant Proc 2003; 35: 154S-156S
17. Schwarz C, Bohmig GA, Steininger R, Mayer G, Oberbauer R. Impaired phosphate handling of renal allografts is aggravated under rapamycin-based immunosuppression. Nephrol Dial Transplant 2001; 16: 378-382
18. Turkowski-Duhem A, Kamar N, Cointault O et al. Predictive factors of post-renal transplant anemia. Transplant Proc 2005; 37: 1009-1011
19. Augustine JJ, Knauss TC, Schulak JA et al. Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am J Transplant 2004; 4: 2001-2006
20. Panwalkar A, Verstovsek S, Giles FJ. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 2004; 100: 657-666